Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems

Roche announced the launch of the Institute of Human Biology (IHB) focussing on advancing research in the field of human model systems such as organoids. Leveraging human model systems, the institute aims to accelerate drug discovery and development by improving the understanding of how organs function and how diseases develop. Ultimately, this will help to bring medicines to patients faster. These efforts will also enable early testing of which drug candidates are safe and which molecules would work best for each patient. Human model systems are miniature 2D or 3D living 'replicas' of human tissues and organs that scientists create from human stem cells. By mirroring human and disease biology more accurately than animal models, they can also help reduce the reliance on animal testing. In addition, human model systems may enable the discovery of new human biology (in health and disease) and identification of drug targets that are impossible to find with classical discovery approaches. "Human model systems such as organoids are the future of our industry. They have the potential to enhance almost all the steps involved in the research and development of an innovative medicine," says Prof. Dr. Hans Clevers, Head of Pharma Research and Early Development (pRED) at Roche and a pioneer in the field of organoids. "The IHB will address long-standing and urgent challenges in drug discovery and development with the ambition to bring more effective and safer medicines to patients faster." Thanks to a new innovative set-up of the institute, scientists and bioengineers from academia and the pharmaceutical industry will work together at the newly launched institute based in Basel, Switzerland. Together, they will study human biology and advance the broad adoption of human model systems in pharmaceutical research and development as well as in clinical practice. The researchers at the IHB can pursue exploratory basic research with great scientific freedom and also apply the latest basic research and cutting-edge technology and bioengineering know-how to real-world challenges. The insights gained will not only inform Roche

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!